Literature DB >> 4600204

Interaction between doxycycline and some antiepileptic drugs.

O Penttilå, P J Neuvonen, K Aho, R Lehtovaara.   

Abstract

The mean half life of doxycycline given to seven patients on long-term diphenylhydantoin treatment was 7.2 +/- 0.4 hours. In five patients on long-term carbamazepine treatment the half life was 8.4 +/- 1.4 hours. In four patients on combined diphenylhydantoin and carbamazepine treatment the half life was 7.4 +/- 0.7 hours. All these were significantly shorter than a mean half life of 15.1 +/- 1.0 hours when doxycycline was given to nine control patients. Therefore doxycycline in normal doses given to patients taking diphenylhydantoin or carbamazepine may fail to maintain the minimum inhibitory concentration necessary for proper bacteriostasis. When doxycycline is given in association with agents known to induce drug metabolism the serum concentration of the antibiotic should be watched to see that bacteriostatic levels are maintained.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4600204      PMCID: PMC1610633          DOI: 10.1136/bmj.2.5917.470

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

Review 1.  Clinically important drug interactions.

Authors:  L F Prescott
Journal:  Drugs       Date:  1973       Impact factor: 9.546

2.  Sulthiame (Ospolot) as inhibitor of diphenylhydatoin metabolism.

Authors:  J M Hansen; M Kristensen; L Skovsted
Journal:  Epilepsia       Date:  1968-03       Impact factor: 5.864

3.  Pharmacological implications of microsomal enzyme induction.

Authors:  A H Conney
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

4.  Dose-dependent enzyme induction.

Authors:  A Breckenridge; M L Orme; L Davies; S S Thorgeirsson; D S Davies
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

6.  Clinical implications of enzyme induction.

Authors:  A Breckenridge; M Orme
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

7.  Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man.

Authors:  J M Hansen; K Siersboek-Nielsen; L Skovsted
Journal:  Clin Pharmacol Ther       Date:  1971 May-Jun       Impact factor: 6.875

8.  Interaction between doxycycline and barbiturates.

Authors:  P J Neuvonen; O Penttilä
Journal:  Br Med J       Date:  1974-03-23
  8 in total
  21 in total

1.  Effect of enzyme induction on bioavailability of hetacillin in patients treated with anticonvulsants and chlorpromazine.

Authors:  P Galanopoulou; C Karageorgiou; K Dimakopoulou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

2.  Possible implications of doxycycline-rifampin interaction for treatment of brucellosis.

Authors:  J D Colmenero; L C Fernández-Gallardo; J A Agúndez; J Sedeño; J Benítez; E Valverde
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 3.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 4.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

5.  Interactions with the absorption of tetracyclines.

Authors:  P J Neuvonen
Journal:  Drugs       Date:  1976       Impact factor: 9.546

6.  Sinusitis, bronchitis, and mycoplasmal pneumonia.

Authors:  G A Pankey
Journal:  Bull N Y Acad Med       Date:  1978-02

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 8.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of carbamazepine.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.